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IS ANTIMULLERIAN HORMONE PREDICTIVE
OF OUTCOMES AFTER PGT-A IN PATIENTS
WITH RECURRENT PREGNANCY
LOSS? Gayathree Murugappan, MD,a Lora K. Shahine,
MD,b Ruth B. Lathi, MD.c aStanford University Medical Center, Sunnyvale,
CA; bPaciﬁc Northwest Fertility and IVF Specialists, Seattle, WA; cStanford
University Medical Center, SUNNYVALE, CA.
OBJECTIVE: Serum biomarkers of ovarian reserve have been utilized in
non-RPL cohorts to stratify patients who may beneﬁt from PGT-A. The goal
of this study was to determine if AMH levels are predictive of outcomes in
RPL patients pursuing PGT-A.
DESIGN: Retrospective cohort study.
MATERIALS AND METHODS: Unexplained RPL patients undergoing
PGT-A at two fertility centers from 2009-2018 were included. All patients
with the intent to perform PGT-A (trophectoderm biopsy and 24 chromosome
screening) were included regardless of ﬁnal cycle outcome. Pregnancy loss
was deﬁned as loss of pregnancy from conception (bHCG level >5mIU/
mL) through twenty weeks gestation.
RESULTS: 157 patients underwent 191 retrievals (RET), 146 of which
completed PGT-A. Patient demographics and outcomes stratiﬁed by
AMH<1 ng/mL and AMHR1 ng/mL are shown in Table 1. Patients with
AMH < 1 ng/mL were signiﬁcantly older with similar BMI and number of
prior losses compared to patients with AMH R1 ng/mL. Patients with
AMH <1 ng/mL had fewer oocytes (p<0.01) and a higher average aneu-
ploidy rate (p¼0.02) compared to patients with AMHR1 ng/mL. In a regres-
sion model adjusting for age, AMH is not a signiﬁcant predictor of having at
least one euploid blastocyst (p¼0.10, CI 0.97-1.43), reaching ET (p¼0.97, CI
0.84-1.18), achieving pregnancy (p¼0.42, CI 0.82-1.09), achieving live birth
(p¼0.12, CI 0.86-1.02) or undergoing pregnancy loss (p¼0.42, CI 0.90-.28).
CONCLUSIONS: Although ovarian reserve is associated with IVF suc-
cess rates, we report that RPL patients with diminished ovarian reserve
(DOR) have similar likelihood of achieving pregnancy and live birth with
PGT-A compared to RPL patients with AMH > 1 ng/mL. Future studies
should incorporate total cycle potential in evaluation of clinical outcomes
and consider a lower AMH cutoff for evaluating DOR.
Reference: None.
SUPPORT: None.
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MANAGEMENTOF EARLY PREGNANCY LOSSWITH
MIFEPRISTONE AND MISOPROSTOL: CLINICAL
PREDICTORS OF SUCCESS FROM A RANDOMIZED
TRIAL. Sarita Sonalkar, MD MPH,a
Nathanael C. Koelper, MPH,a Mitchell D. Creinin, MD,b
Jessica M. Atrio, MD, MSc,c Mary D. Sammel, ScD,a
Courtney A. Schreiber, MD, MPH.a aUniversity of Pennsylvania, Philadel-
phia, PA; bUniversity of California - Davis, Sacramento, CA; cMonteﬁore
Hospital & Albert Einstein College of Medicine, Bronx, NY.
OBJECTIVE: To evaluate characteristics associated with treatment success
in women receiving medical management for early pregnancy loss (EPL).
DESIGN:We performed a secondary analysis of a randomized trial of 300
participants1 comparing mifepristone-misoprostol to misoprostol alone for
EPL treatment.
MATERIALS AND METHODS: We tested the ability of characteristics
associated with misoprostol success in a previous study2, vaginal bleeding
and parity of 0 or 1, to discriminate successful from failed treatment in
each arm of our study population and in the combined cohort using
receiver-operating characteristic curves. We calculated the area under the
curve (AUC) to quantify the ability of the score to discriminate between treat-
ment success or failure in each arm as well as in the entire cohort. Using
multivariable logistic regression, we then assessed our study population for
other predictors of treatment success in both treatment groups, with and
without mifepristone.
RESULTS: The clinical characteristics of vaginal bleeding and parity of
0 or 1 did not predict success above chance alone in the misoprostol-alone
arm (AUC¼0.55, 95% CI 0.44-0.65), the mifepristone pretreatment arm
(AUC¼0.59, 95% CI 0.45-0.72) or the combined cohort (AUC¼0.56,
95% CI 0.48-0.64). No other baseline clinical factors predicted treatment
success in the misoprostol-alone or mifepristone pretreatment arms indi-
vidually. In the full cohort, randomization to pretreatment with mifepris-
tone was a positive predictor of treatment success (aOR 2.51, 95% CI
1.43-4.43), while smoking was a negative predictor (aOR 0.47, 95% CI
0.23-0.97).
CONCLUSIONS: Pretreatment with mifepristone is a more useful
intervention than applying baseline clinical factors to maximize treatment
success in women undergoing medical management of EPL with
misoprostol.
References: 1. Schreiber, CA, Creinin,MD,Atrio, J, Sonalkar, S, Ratcliffe,
SJ, Barnhart, KT. Mifepristone pretreatment for the medical management of
early pregnancy loss. N Engl J Med. 2018;378(23):2161-70.
2.A^ Creinin, MD, Huang, X, Westhoff, C, Barnhart, K, Gilles, JM, Zhang,
J, et al. Factors related to successful misoprostol treatment for early preg-
nancy failure. Obstet Gynecol. 2006;107(4):901-7.
SUPPORT: Supported by the National Institute of Child Health and Hu-
man Development of the National Institutes of Health (Eunice Kennedy
Shriver award number R01-HD0719-20 [to Dr. Schreiber] and Women’s
Reproductive Health Research award number K12-HD001265-18 [to Dr. So-
nalkar]), and a Society of Family Planning Research FundMidcareer Mentor
Award (Schreiber).
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THECELLULARROLES OFRPL-PROTEASEA IN THE
RECURRENT PREGNANCYLOSS. Chang-Zhu Pei, MD,a
Jun-Hyeok Park, MS,a Bum Chae Choi, MD, PHD,b
In Kyung Oh, MD,b Hyo Young Park, PHD,b
Kwang-HyunBaek, PHD.a aCHAUniversity, Seongnam-Si Gyeonggi-Do, Ko-
rea, Republic of (South); bCreation and Love Women’s Hospital, Gwang-ju,
Korea, Republic of (South).
OBJECTIVE: To investigate cellular functions of RPL-serine protease A
on cell apoptosis, invasion, and proliferation that lead to recurrent pregnancy
loss (RPL).
AMH <1 ng/mL n¼42 RET AMHR1 ng/mL n¼149 RET P-value
Age, yrs (mean  SD, range) 37.64.2 (28-44) 36.23.6 (29-43) 0.031
No. of prior losses (mean  SD, range) 3.11.2 (2-6) 3.11.0 (2-7) 0.861
BMI, kg/m2 (mean  SD, range) 24.13.6 (18-31) 23.23.5 (17-39) 0.151
No. of oocytes (mean  SD, range) 11.19.2 (1-41) 18.88.5 (4-43) <0.011
% of cycles reaching euploid ET (%, n) 48% (n¼20/42) 59% (n¼88/149) 0.182
% of cycles transferring untested embryos
(%, n)
21% (n¼9/42) 13% (n¼20/149) 0.202
% of cycles not reaching ET (%, n) 31% (n¼13/42) 28% (n¼41/149) 0.662
PR per RET (%, n) 40% (n¼17/42) 49% (n¼73/149) 0.952
Avg. aneuploidy rate (mean  SD) 69%  84% 53%  28% 0.021
PR per PGT-A cycle (%, n) 52% (n¼14/27) 50% (n¼60/119) 0.892
PR per euploid ET (%, n) 70% (n¼14/20) 68% (n¼60/88) 0.822
Pregnancy loss rate per pregnancy (%, n) 35% (n¼6/17) 30% (n¼22/73) 0.462
LBR per RET (%, n) 26% (n¼11/42) 34% (n¼51/149) 0.332
1Student’s T Test, 2-tailed, unpaired.
2Chi-squared analysis.
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